Pharmacyclics — Technical Presentation (December 2012)
30 slides from Pharmacyclics's technical presentation, Dec 11, 2012
Slide 1: Disclosures
Disclosures WynbDHAmM H. WiLson, MD PHD * RESEARCH FUNDING: National Cancer Institute » EMPLOYEE: National Cancer Institute » STOCKHOLDER: None » CONSULTANT: None * SCIENTIFIC ADVISORY BOARD: None
Slide 2: Ibrutinib Has Preferential Activity in ABC Subtype of Relapsed/Refractory DLBCL
The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study Wyndham H. Wilson MD, PhD’, John F. Gerecitano MD, PhD?,
Slide 3: Molecular Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL)
Molecular Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) ABC DLBCL jes Probability GCB DLBCL Probability FOXP1 IRA 1-16 BLNK e039 Gyciin D2 Pim-t IgM p10 JAW BOLE Lmoz Amyb ABC DLBCL < > 274 DLBCL Biopsy Samples
Slide 4: Molecular Subtype Predicts Outcome With R-CHOP
Molecular Subtype Predicts Outcome With R-CHOP 10. 10 os. 08 Probability °° oe of survival 4 a 02 02 P<0.001 P<0.001 + 0.01 ° 1 203 46 o 4 2 8 4 58 Progression-free survival (yrs) Overall survival (yrs) Ml ccs pLecL 1) asc DLBCL Lenz et al, N Eng! J Med. 2008; 369: 2313,
Slide 5: Chronic Active B-Cell Receptor Signaling Activates NF-kB in ABC DLBCL
Chronic Active B-Cell Receptor Signaling Activates NF-kB in ABC DLBCL ‘Chronic Active BCR signaling a @ ig he SB xB kinase J NEXB pathway ¥
Slide 6: Chronic Active B-Cell Receptor Signaling Activates NF-kB in ABC DLBCL
Chronic Active B-Cell Receptor Signaling Activates NF-kB in ABC DLBCL e. 21% as iB kinase 10% = pathway ¥
Slide 7: MYD88 Signaling Activates NF-kB in ABC DLBCL
MYD88 Signaling Activates NF-kB in ABC DLBCL Chronic Active Constitutive BCR signaling MYD88 signaling “i | SB ix kinase { NEXB pathway ¥ Survival
Slide 8: Targeting B-Cell Receptor Signaling Through Inhibition of BTK
Targeting B-Cell Receptor Signaling Through Inhibition of Bruton Tyrosine Kinase (BTK) Chronic Active Constitutive BCR signaling MYD88 signaling @, Me OD IxB kinase t NEXB pathway ¥ Survival
Slide 9: Ibrutinib: A First-in-Class Inhibitor of BTK
Ibrutinib: A First-in-Class Inhibitor of BTK » Forms covalent bond with cysteine-481 in BTK - High BTK specificity * ICgo = 0.5 nM * Daily oral dosing produces 24-hr BTK inhibition » Blocks NF-KB in DLBCL cell lines
Slide 10: Ibrutinib activity will be restricted to ABC DLBCL
cy — * Ibrutinib activity will be restricted to ABC DLBCL 10
Slide 11: Study Hypothesis
Study Hypothesis * Ibrutinib activity will be restricted to ABC DLBCL ° Ibrutinib activity will be dependent on pathogenetic events within the BCR pathway "
Slide 12: Study Design: PCYC-1106-CA
Study Design: PCYC-1106-CA Multi-center (n=14), open-label, phase II study of ibrutinib in relapsed/refractory de novo DLBCL Treatment: 560 mg PO daily to progression (28 day cycle) Primary objective: — Evaluate ibrutinib in relapsed/refractory de novo ABC and GCB DLBCL Secondary objective: — Evalua
Slide 13: Patient Eligibility
Patient Eligibility * Pathologically confirmed de novo DLBCL * Men and women 2 18 years of age ° ECOG performance status < 2 * Archival tissue for central review ° Prior treatment: » Progressive disease after autologous transplant (ASCT) * Or considered ineligible for ASCT as outlined in protocol °
Slide 14: Patient Characteristics
Patient Characteristics Characteristics Age, median (range) years. Sex (Male), n (%) ECOG PS 2, n (%) IPI (HI/High), n (%) Time from diagnosis, median (range) months Prior regimens, median (range) Prior ASCT, n (%) Refractory disease, n (%) Refractory disease — PR or less to last therapy Total (N=70
Slide 15: Patient Characteristics by GEP Analysis
Patient Characteristics by GEP Analysis Characteristics* ABC GCcB Unclassified Unknown (N=29) (N=20) (N=16) (N=5) MediansAge yrs (range) »62 (34-89) 65 (28:92) 65)(44-85) 65 (58-78) Sex (Male) 69% 70% 81% 60% ECOG PS2 7% 20% 25% 40% IPI (HI/High) 61% 58% 54% 60% Time from diagnosis 19 (5-74) 17 (11-
Slide 16: Patient Characteristics by GEP Analysis
Patient Characteristics by GEP Analysis Characteristics* Median Age yrs (range) Sex (Male) ECOG PS2 IPI (HUHigh) Time from diagnosis median (range) Prior regimens median (range) Prior ASCT Refractory disease No statistically significant rences ABC GCB (N=29) (N=20) 62 (34-89) 65 (28-92) 70% 20% 61%
Slide 17: Grade 3 or Higher AEs >3% Incidence
Grade 3 or Higher AEs >3% Incidence (Unrelated and related AEs) Hematologic AEs Lymphocyte count decreased Neutropenia Trrombocytopenia —— rade r wee Grade 4 Bascal ee Grade § Platelet count decreased ‘hte blood cal count decreases 0% «= 10% = 20% 80% 40% SO OOKTOK BO T00H, Non-Hematologic AEs Fatig
Slide 18: Overall Response Rate (ITT Population)
Percent of patients (%) Overall Response Rate (ITT Population) 50 4 40 | 30 | 23% 16/70 — 20 | uCR 10 4 o/ ORR 18
Slide 19: Waterfall Plot of Maximum Decrease in Bi-dimensional Measurements
Waterfall Plot of Maximum Decrease in Bi-dimensional Measurements % Change from Baseline SPD 130} -20 -70 -120 Wi vainown 3) Only includes pts with post baseline LN measurements * Best response was PD due to clinical progression 19
Slide 20: Response in ABC DLBCL vs GCB DLBCL
% Response (CR#PR) 100 P=0.007 41% 12/29 PRS% 1/20 eee ABC DLBCL GCBDLBCL
Slide 21: Time on Study Treatment in ABC and GCB DLBCL
Time on Study Treatment in ABC and GCB DLBCL ABC DLBCL GCB DLBCL oO 2 4 6 8 10 12 Months on study Patient still on ibrutinib > 2
Slide 22: Overall Survival in ABC and GCB DLBCL
Overall Survival in ABC and GCB DLBCL Probability of Survival ‘Overall Survival (months) ‘ABC GcB ITT Population 29 20 Median (95% Cl) of OS (months) 9.76 (3.88, NR) 3.35 (1.22, NR) »
Slide 23: Analysis of Response Rate within Mutation Subgroups
Analysis of Response Rate within Mutation Subgroups * Mutations in tumor samples analyzed by PCR amplification and Sanger DNA sequencing * ABC DLBCL tumors were analyzed for mutations in CD79B, MYD88 and CARD11 * Includes 29 ABC DLBCL cases present study (PCYC-1106) and 10 ABC DLBCL cases from a pil
Slide 24: CD79B Mutant ABC DLBCL Predicts a High Rate of Response to Ibrutinib
CD79B Mutant ABC DLBCL Predicts a High Rate of Response to Ibrutinib 100 2 So a So 40 20 Percent Response (CR + PR) 04 CD79B: 71% Mutant NCI data 24
Slide 25: Ibrutinib Response in ABC DLBCL Does Not Require B Cell Receptor Mutation
Ibrutinib Response in ABC DLBCL Does Not Require B Cell Receptor Mutation 100 S a 2 r=) So So Percent Response (CR + PR) y 8 04 CD79B: 71% Mutant NCI data 25
Slide 26: MYD88 L265P Plus CD79B Mutations Identify Ibrutinib-Responsive ABC DLBCL
MYD88 L265P Plus CD79B Mutations Identify Ibrutinib-Responsive ABC DLBCL 100 S a 2 r=) So So Percent Response (CR + PR) y 8 0 71% SI7 34% 10/29 80% CD79B: MYD88: Mutant NCI data 28
Slide 27: MYD88 L265P Without CD79B Mutation Predicts Ibrutinib Resistance
MYD88 L265P Without CD79B Mutation Predicts Ibrutinib Resistance in ABC DLBCL 100 S a 2 r=) So So Percent Response (CR + PR) y 8 0 71% 34% 5/7 10/29 80% o/s CD79B: MYD88: Mutant WT Mutant WT Mutant Mutant NCI data ar
Slide 28: CARD11 Mutant ABC DLBCL Does Not Respond to Ibrutinib
CARD11 Mutant ABC DLBCL Does Not Respond to Ibrutinib 100 NCI data 80% 2 So 71% a So S r=) 34% Percent Response (CR + PR) y 8 0 SI7 10/29 O15 04 CD79B: Mutant WT Mutant WT MYD88: Mutant Mutant CARD11: Mutant 28
Slide 29: Conclusions
Conclusions Ibrutinib, a selective covalent inhibitor of BTK, induced a high response rate in relapsed/refractory ABC DLBCL Ibrutinib had marginal activity in GCB DLBCL, supporting the use of the ABC DLBCL molecular subtype as a biomarker for activity CD79B mutant tumors responded frequently to ibru
Slide 30: Acknowledgements
Acknowledgements *Yandan Yang 4 toni unkel ‘Sameer Jhavar SrirauwBatesulamanian Roland Schmitz Mei Cheng Art Shafér. = Davina Moussa > Lower “tipo Chan Linda.Gat ~~ Soseniiy? sine ib SS. : > Deborah ree 3, Cian er rel a Geretitano a samen ) AndreGoy— —__ Rebecca Elstromr * Dang ad —<. Y sven deVos ‘
Pharmacyclics — Technical Presentation (December 2012) on 6ix